This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment in the clinical trial designated TRx-014-001 at termination of that study. Treatment for each individual patient will continue for as long as the treating physician feels there is benefit to the patient. This current protocol covers each patient for 12 months in the first instance.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
111
Gelatin capsule, tid
Cognitive ability measured by the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) and by the Mini-Mental State Examination (MMSE).
Time frame: 0, 26 and 52 weeks
Dementia severity assessed by the Clinical Dementia Rating - sum of the boxes (CDR-sb).
Time frame: 0, 26 and 52 weeks
Daily living activities assessed by the Alzheimer's Disease functional Assessment and Change Scale (ADFACS)
Time frame: 0, 26 and 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.